Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

590 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord.
Socio-economic Inequalities and HIV Writing Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord; Lodi S, Dray-Spira R, Touloumi G, Braun D, Teira R, D'Arminio Monforte A, Gallois A, Zangerle R, Spire B, Dabis F, Stähelin C, Termote M, Kirk O, Chêne G, Egger M, del Amo J. Socio-economic Inequalities and HIV Writing Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, et al. AIDS. 2014 Sep 24;28(15):2297-306. doi: 10.1097/QAD.0000000000000410. AIDS. 2014. PMID: 25313585
Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.
d'Arminio Monforte A, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC, Abeli C, Rusconi S, Sollima S, Balotta C, Musicco M, Galli M, Moroni M. d'Arminio Monforte A, et al. AIDS. 1998 Sep 10;12(13):1631-7. doi: 10.1097/00002030-199813000-00010. AIDS. 1998. PMID: 9764782 Clinical Trial.
Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, Uberti-Foppa C, Pradier C, D'Arminio Monforte A, Schneider MM, Lundgren JD; Eight European Study Groups. Ledergerber B, et al. N Engl J Med. 2001 Jan 18;344(3):168-74. doi: 10.1056/NEJM200101183440302. N Engl J Med. 2001. PMID: 11188837 Free article.
When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study.
Cozzi Lepri A, Phillips AN, d'Arminio Monforte A, Castelli F, Antinori A, de Luca A, Pezzotti P, Alberici F, Cargnel A, Grima P, Piscopo R, Prestileo T, Scalise G, Vigevani M, Moroni M; ICONA Study Group. Cozzi Lepri A, et al. AIDS. 2001 May 25;15(8):983-90. doi: 10.1097/00002030-200105250-00006. AIDS. 2001. PMID: 11399980 Clinical Trial.
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration. Egger M, et al. Lancet. 2002 Jul 13;360(9327):119-29. doi: 10.1016/s0140-6736(02)09411-4. Lancet. 2002. PMID: 12126821
590 results